Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4 CNS 4 Genitourinary 3 Gastrointestinal 3 Sarcoma 2 Plasma cell 2 Myeloid 2 Tumor-Agnostic 1 Thoracic 1 Other hematologic neoplasm 1 Head & Neck 1 Gynecologic 1 Dermatologic 1 Breast 1

Conditions

Interventions

pembrolizumab 17 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 Bevacizumab 8 Paclitaxel 7 Biopsy 7 Nivolumab 6 atezolizumab 5 Surveys and Questionnaires 4 Standard of Care 4 Radiosurgery 4 Practice Guidelines as Topic 4 Pemetrexed 4 Oxaliplatin 4 Cyclophosphamide 4 Carboplatin 4 osimertinib 3 niraparib 3 durvalumab 3 cemiplimab 3 avelumab 3 Radiotherapy 3 Radiation 3 Leucovorin 3 Irinotecan 3 Ipilimumab 3 Interviews as Topic 3 Fluorouracil 3 trastuzumab deruxtecan 2 trametinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × larotrectinib × Tumor-Agnostic × Clear all

NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting

154 enrolled 2 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡